The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
17 May 2024
Historique:
accepted: 11 04 2024
received: 24 07 2023
revised: 04 04 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: aheadofprint

Résumé

Among the most common genetic alterations in the myelodysplastic syndromes (MDS) are mutations in the spliceosome gene SF3B1. Such mutations induce specific RNA missplicing events, directly promote ring sideroblast (RS) formation, and generally associate with more favorable prognosis. However, not all SF3B1 mutations are the same, and little is known about how distinct hotspots influence disease. Here we report that the E592K variant of SF3B1 associates with high-risk disease features in MDS, including a lack of RS, increased myeloblasts, a distinct co-mutation pattern, and a lack of the favorable survival seen with other SF3B1 mutations. Moreover, compared to other hotspot SF3B1 mutations, E592K induces a unique RNA missplicing pattern, retains an interaction with the splicing factor SUGP1, and preserves normal RNA splicing of the sideroblastic anemia genes TMEM14C and ABCB7. These data have implications for our understanding of the functional diversity of spliceosome mutations, as well as the pathobiology, classification, prognosis, and management of SF3B1-mutant MDS.

Identifiants

pubmed: 38759096
pii: 516137
doi: 10.1182/bloodadvances.2023011260
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

In Young Choi (IY)

Johns Hopkins University, Baltimore, Maryland, United States.

Jonathan P Ling (JP)

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.

Jian Zhang (J)

Columbia University, New York, New York, United States.

Eric Helmenstine (E)

The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States.

Wencke Walter (W)

Munich Leukemia Laboratory, Munich, Germany.

Panagiotis Tsakiroglou (P)

The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States.

Riley E Bergman (RE)

Vanderbilt University, Nashville, Tennessee, United States.

Céline Philippe (C)

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

James L Manley (JL)

Columbia University, New York, New York, United States.

Kevin Rouault-Pierre (K)

Queen Mary University of London, London, United Kingdom.

Bing Li (B)

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.

Daniel Howard Wiseman (DH)

The University of Manchester, Manchester, United Kingdom.

Kiran Batta (K)

The University of Manchester, Manchester, United Kingdom.

Madhu M Ouseph (MM)

Weill Cornell Medicine, New York, New York, United States.

Elsa Bernard (E)

Gustave Roussy, Villeuif, France.

Benjamin Dubner (B)

The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States.

Xiao Li (X)

Shanghai Jiao Tong University Affiliated Sixth People's Hospital, shanghai, China.

Torsten Haferlach (T)

MLL Munich Leukemia Laboratory, Munich, Germany.

Anna Koget (A)

Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, United States.

Salman Fazal (S)

Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, United States.

Tania Jain (T)

Johns Hopkins University, Baltimore, Maryland, United States.

Christopher D Gocke (CD)

Johns Hopkins Medical Institutions, Baltimore, Maryland, United States.

Amy E DeZern (AE)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States.

William Brian Dalton (WB)

The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States.

Classifications MeSH